Iranian Journal of Diabetes and Obesity
IJDO
Medical Sciences
http://ijdo.ssu.ac.ir
1
admin
2008-6792
2345-2250
8
7
14
8888
13
en
jalali
1404
4
1
gregorian
2025
7
1
17
3
online
1
fulltext
en
The Impact of Orlistat on Diabetic Patients Experiencing Overweight and Constipation: A Randomized Clinical Trial
تخصصي
Special
پژوهشي
Research
<span style="font-size:11pt"><span style="text-justify:inter-ideograph"><span style="line-height:115%"><span calibri="" style="font-family:"><b><span style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">Objective</span></span></span></b><b><span lang="EN" style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">:</span></span></span></b> <span style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">Obesity is a global health concern, the use of Orlistat as an anti-obesity drug, has shown promise in managing the constipation and blood sugar levels in diabetic patients. This study aimed to evaluate the impact of Orlistat on diabetic patients experiencing both overweight and constipation.</span></span></span></span></span></span></span><br>
<span style="font-size:11pt"><span style="text-justify:inter-ideograph"><span style="line-height:115%"><span calibri="" style="font-family:"><b><span style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">Materials and Methods:</span></span></span></b> <span style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">A total of 80 overweight and constipated diabetic patients were randomly enrolled. Participants were randomly assigned to either the intervention or control group. The intervention group received 120 mg Orlistat with lunch for three months, while the control group received placebo, taken once daily with lunch for the same duration. Clinical and paraclinical parameters, including body mass index (BMI), constipation, fasting blood sugar (FBS), HbA1C, triglycerides (TG), cholesterol (CHL), high-density lipoprotein (HDL), creatinine (Cr), aspartate transaminase (AST), alanine transaminase (ALT), and blood sugar two hours postprandial (BS-2HPP), were assessed before and after the intervention.</span></span></span></span></span></span></span><br>
<span style="font-size:11pt"><span style="text-justify:inter-ideograph"><span style="line-height:115%"><span calibri="" style="font-family:"><b><span style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">Results:</span></span></span></b> <span style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">Significantly, the BS-2HPP and ALT decreased in the interventiom group. Additionally, there was a noteworthy improvement in constipation within the intervention group compared to the control group.</span></span></span></span></span></span></span><br>
<span style="font-size:11pt"><span style="text-justify:inter-ideograph"><span style="line-height:115%"><span calibri="" style="font-family:"><b><span lang="EN" style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">Conclusion:</span></span></span></b> <span style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">Orlistat demonstrates some effectiveness in improving clinical parameters in diabetic patients with obesity and constipation. While the drug shows notable efficacy in alleviating constipation, its impact on other related parameters is not statistically significant. No significant side effects were observed with Orlistat.</span></span></span></span></span></span></span><br>
Diabetes mellitus, Orlistat, Constipation, Obesity, Clinical trial
150
158
http://ijdo.ssu.ac.ir/browse.php?a_code=A-10-30-450&slc_lang=en&sid=1
Mohsen
Zabihi